Almac, DSM sign collaboration agreement in biocatalysis

Wednesday, October 10, 2012 12:24 PM

Global service provider Almac has signed a collaboration agreement with DSM Pharmaceutical Products, the custom manufacturing and technology business of Royal DSM, in the field of biocatalysis to provide sustainable manufacturing services to the pharmaceutical industry.

The agreement grants both parties access to their enzyme platform technologies, services and expertise for the manufacturing of active pharmaceutical ingredients (APIs). Almac’s expertise in rapid enzyme identification, scale-up and implementation into early phase projects complements DSM’s experience and track record of over 30 commercial manufacturing bioprocesses run on a multi-ton scale. This will give customers of either party access to enzyme expertise and assets resulting in cost-effective, green processing at all phases of development from preclinical to commercial manufacturing scale.  This collaboration will also enable Almac to offer its customers a preferred partner for large-scale production.

“This collaboration has come at the right time as more and more customers need scalable green technologies to access difficult-to-make chiral chemicals,” said Tom Moody, head of biocatalysis, Almac. "Having access to the right enzymes today will drive ‘hit to process.’ The introduction of enzymes into processes earlier in the drug discovery pipeline will therefore help to drive cost down as the projects move forward.”

"One important success factor for implementing enzymatic routes is access to a diverse range of biocatalysts,” said Daniel Mink, corporate scientist biocatalysis and (bio)-organic chemistry, DSM. “DSM is continuously expanding its unique enzyme collection of more than 3,000 enzymes through in-house development as well as innovative partnering models. The collaboration with Almac completes the latest phase in this process. Together we will be able to offer a complete package serving the pharmaceutical industry at all stages of development from preclinical to commercial scale—bringing biocatalysis to the next level.”

Share:          
CWWeekly

March 2

Huntingdon Life Sciences-Harlan prepares for rebranding and U.S. expansion to compete with early phase CROs Covance, CRL

Patients' increased sharing of clinical trial experiences through social media can help sponsors improve outcomes, enrollment

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

March

Novo Nordisk, Takeda, Servier, Celgene among top sponsors
New gains seen from patient- and site-centric initiatives

Patient reported outcomes take center stage
FDA combining PROs, clinical outcomes in its approval decisions

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

February

Study grants market breaks $13 billion
Volume of clinical activity rising while growth in grant spending slows

Revisiting eClinical Technology Solutions Adoption
While use of established solutions grows, sponsors hesitate on newer tools

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs